Open AccessCoenzyme Q<sub>10</sub>
Author(s) -
Albert E. Raizner
Publication year - 2019
Publication title -
methodist debakey cardiovascular journal
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.552
H-Index - 23
eISSN - 1947-6094
pISSN - 1947-6108
DOI - 10.14797/mdcj-15-3-185
Subject(s) - medicine , clinical trial , randomized controlled trial , heart failure , intensive care medicine , physical therapy
Coenzyme Q 10 (CoQ 10 ) is among the most widely used dietary and nutritional supplements on the market. CoQ 10 has several fundamental properties that may be beneficial in several clinical situations. This article reviews the pertinent chemical, metabolic, and physiologic properties of CoQ 10 and the scientific data and clinical trials that address its use in two common clinical settings: statin-associated myopathy syndrome (SAMS) and congestive heart failure (CHF). Although clinical trials of CoQ 10 in SAMS have conflicting conclusions, the weight of the evidence, as seen in meta-analyses, supports the use of CoQ 10 in SAMS overall. In CHF, there is a lack of large-scale randomized clinical trial data regarding the use of statins in patients receiving contemporary treatment. However, one relatively recent randomized clinical trial, Q-SYMBIO, suggests an adjunctive role for CoQ 10 in CHF. Recommendations regarding the use of CoQ 10 in these clinical situations are presented.